Trials / Available
AvailableNCT07319585
Managed Access Programs for EXV811, Atrasentan
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to EXV811, Atrasentan
Detailed description
CEXV811A12004M - Available - Managed Access Program (MAP) Cohort Treatment Plan CEXV811A12004M to provide access to Atrasentan for IgA nephropathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atrasentan | Patients receive atrasentan |
Timeline
- First posted
- 2026-01-06
- Last updated
- 2026-01-22
Source: ClinicalTrials.gov record NCT07319585. Inclusion in this directory is not an endorsement.